Avalo Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for immune-mediated inflammatory diseases. The company focuses on the IL-1β pathway, with its lead product candidate, abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody, currently in a Phase 2 trial for hidradenitis suppurativa. Avalo is also advancing AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody designed to extend dosing intervals. The company acquired rights to abdakibart through the acquisition of AlmataBio in 2024, which included a worldwide exclusive license from Eli Lilly and Company. Avalo’s pipeline includes legacy programs such as quisovalimab (AVTX-002), AVTX-006, AVTX-008, and AVTX-913, for which it is exploring strategic alternatives. The company serves patients with chronic inflammatory conditions, including hidradenitis suppurativa, and operates in markets including the United States, Canada, Europe, and Australia.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage avalotx.com
Sector Healthcare IR page ir.avalotx.com
Tags
immune-mediated inflammatory diseases, hidradenitis suppurativa, monoclonal antibodies, il-1β pathway, clinical-stage, biologics, abdakibart, AVTX-009, AVTX-010, quisovalimab, AVTX-002, AVTX-006, AVTX-008, AVTX-913, AlmataBio, Eli Lilly, Leap Therapeutics, FL-101, LY2189102, LOTUS
Press page ir.avalotx.com/news-events-presentations/press-releases

Metrics

Valuation  
Market cap $ 826.641M
Market cap (USD) $ 826.641M
P/E -5.83
PEG —
P/BV 1.89
P/S —
P/OCF -13.02
P/FCF -16.06
Dividend yield —
Turnover / mcap —
Returns  
ROE -72.4%
ROI -116.4%
ROIC -81.4%
Profit margin -132,642.4%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 3
Quality score -81.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 59K 441K 1.924M 18.051M 5.398M 6.699M 6.75M 18.327M 27.813M — — —
Net profit -78.259M -35.129M -31.544M -41.658M -84.376M -63.5M -16.1M -40.1M 11.87M -16.472M -10.49M -16.056M
Free cash flow -51.458M -49.056M -30.68M -26.846M -71.005M -40.602M -19.396M -3.664M 12.496M -14.608M -10.183M -15.538M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 18.16 7.43 9.1 5.04 1.7 — — — — — — —
Price performance 12m 1.44 -0.18 0.81 1.96 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — — 0.00 — — —
Borrowings, current (USD) 2.35M 0.00 1.1M — — — — — — —
Borrowings, non-current (USD) 0.00 0.00 14.3M — — — — — — —
Lease liabilities (USD) — — — 1.27M 1.46M 2.5M 2.24M 1.9M 918,000 427,000
Cash and deposits (USD) 5.13M 2.47M 10.6M 3.61M 18.9M 54.6M 13.2M 7.42M 135M 15.9M
Intangible assets (USD) 0.00 17.7M 31.2M 2.43M 1.59M 38,000 0.00 — — —
Right-of-use assets (USD) — — — 718,626 917,472 2M 1.75M 1.33M 741,000 336,000
Net debt (borrowings + leases - cash) (USD) -2.77M -2.47M 4.83M — — — — — — —
Cash flow detail
Operating cash flow (USD) -14.6M 12.5M -3.1M -19.1M -40.5M -70.9M -26.8M -30.7M -49.1M -51.5M
Purchases of property, plant and equipment (USD) -34,883 -23,325 -564,415 -262,013 -62,659 -113,000 -95,000 — — —
Change in receivables (cash effect) (USD) -132,472 -247,195 -222,530 1.66M -678,101 1.12M 1.06M 0.00 — —
Change in inventories (cash effect) (USD) 0.00 -202,622 -311,199 532,947 18,198 -35,000 18,000 20,000 0.00 —
Change in payables (cash effect) (USD) 332,100 96,065 82,451 1.02M 98,520 796,000 -487,000 -2.44M -163,000 -146,000
Interest paid (cash effect) (USD) -348,888 -72,526 -525,000 -1.05M 0.00 -1.59M -2.93M -1.93M 0.00 —
Income taxes paid (cash effect) (USD) 0.00 -540,000 -354,000 -1.8M -474,000 0.00 0.00 — — —
Share-based compensation (USD) 1.69M 1.16M 2.43M 2.53M 6.79M 8.17M 7.55M 3.48M 5.85M 13.6M
Operating cash flow before change in receivables (USD) -14.4M 12.8M -2.88M -20.8M -39.9M -72M -27.8M -30.7M — —
Free cash flow (OCF - PPE - intangibles) (USD) -14.6M 12.5M -3.66M -19.4M -40.6M -71M -26.8M — — —
Income detail
Research and development expense (USD) 10.1M 4.37M 5.79M 11.8M 32.2M 59.8M 31.3M 13.8M 24.4M 50.1M
↳ 5y CAGR -8.3% -0.8% +37.3% +42.6% +48.2% +19.0% +15.7% +9.2%
Total comprehensive income (USD) — — — — — — — — -35.1M -78.2M
Comprehensive income to owners (USD) — — — — — — — — -35.1M -78.2M
Reported Apr 2, 2018 Apr 2, 2018 Mar 18, 2019 Mar 11, 2020 Mar 8, 2021 Mar 2, 2022 Aug 3, 2023 Mar 29, 2024 Mar 23, 2026 Mar 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Advancing abdakibart toward a registrational Phase 3 program in hidradenitis suppurativa, with initiation planned for the first half of 2027

•Advancing AVTX-010, a next-generation, long-acting anti-IL-1β antibody, toward an Investigational New Drug submission in the first half of 2027

•Cash, cash equivalents and investments of $462.8 million as of September 30, 2026, expected to fund operations into 2029

WAYNE, Pa., Nov. 5, 2026 – Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company focused on developing therapies targeting the IL-1β pathway for immune-mediated inflammatory diseases, today reported financial results for the third quarter of 2026 and provided a business update.

“LOTUS provides a strong clinical foundation for advancing abdakibart toward registrational development in hidradenitis suppurativa,” said Garry Neil, MD, Chief Executive Officer of Avalo. “The efficacy and safety results observed across both dosing regimens, together with the potential for once-monthly administration, give us confidence in abdakibart’s potential to become an important new treatment option for patients with HS.

On November 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an Open Market Sale AgreementSM (the “Jefferies Sales Agreement”), with Jefferies LLC (“Jefferies”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at the Company’s sole discretion, shares of the Company’s common stock, $0.001 par value per share (the “Shares”), through Jefferies. The issuance and sale, if any, of the Shares may be by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended (the “Securities Act”), including, without limitation, sales made directly on the Nasdaq Capital Market (“Nasdaq”).

The Company is not obligated to sell any of the Shares, and Jefferies is not required to sell any specific number or dollar amount of the Shares under the Jefferies Sales Agreement. The Company or Jefferies may suspend or terminate the offering of the Shares upon notice to the other party and subject to other conditions.

September 29, 2026 4:01pm EDT

WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 101,600 shares of common stock (the “Options”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The Options were granted on September 25, 2026 and have an exercise price of $15.47 per share, which is equal to the closing price of Avalo’s common stock on the grant date. The Options will vest as to 25% of the underlying shares of common stock on the one-year anniversary of the applicable employee’s start date of employment, and the balance of the underlying shares of common stock vesting monthly thereafter over 36 months, subject to the applicable employee’s continued service relationship with Avalo through the applicable vesting dates. The Options are subject to the terms and conditions of Avalo’s 2025 Inducement Award Plan and award agreements thereunder.

Prompts

Avalo Therapeutics, Inc. (ticker AVTX), listed in United States.

Company History

Date Change Detail
Aug 26, 2021 Renamed CERECOR INC. → AVALO THERAPEUTICS, INC.

ETFs Holding Avalo Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
TMED 0.34% 4,287 $ 79.224K Jun 30, 2026
VFMO 0.04% 44,584 $ 862.255K Aug 31, 2026
RESM 0.03% 56 $ 1,034.88 Jun 30, 2026
TMSL 0.02% 32,182 $ 594.723K Jun 30, 2026
FSEG 0.01% 42 $ 776.16 Jun 30, 2026
AVSC 0.01% 40,933 $ 301.676K Nov 16, 2026
MSSM 0.00% 1,692 $ 32.723K Aug 31, 2026
DXUV 0.00% 140 $ 1,078.00 Nov 12, 2026
AVUS 0.00% 791 $ 5,829.67 Nov 16, 2026